{"altmetric_id":19699005,"counts":{"readers":{"mendeley":19,"citeulike":2,"connotea":0},"total":{"posts_count":1},"facebook":{"unique_users_count":1,"unique_users":["454973074550762"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa63a3cf058f610008b56","authors":["Tomoko Okamoto","Masafumi Ogawa","Youwei Lin","Miho Murata","Sachiko Miyake","Takashi Yamamura"],"doi":"10.1177\/1756285608093978","first_seen_on":"2017-04-29T11:48:51+00:00","issns":["1756-2856","1756-2864"],"issue":"1","journal":"Therapeutic Advances in Neurological Disorders","last_mentioned_on":1493113982,"links":["https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3002541\/"],"pmcid":"PMC3002541","pmid":"21180560","pubdate":"2008-07-01T00:00:00+00:00","publisher":"SAGE Publications","startpage":"5","title":"Review: Treatment of neuromyelitis optica: Current debate","type":"article","volume":"1","mendeley_url":"http:\/\/www.mendeley.com\/research\/review-treatment-neuromyelitis-optica-current-debate"},"altmetric_score":{"score":0.25,"score_history":{"1y":0.25,"6m":0.25,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":8099079,"mean":6.8881653514065,"rank":7011437,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":8099079,"percentile":1},"similar_age_3m":{"total_number_of_other_articles":233945,"mean":12.613681761447,"rank":190197,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":233945,"percentile":1},"this_journal":{"total_number_of_other_articles":178,"mean":6.3690508474576,"rank":157,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":178,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":6,"mean":1.68,"rank":5,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":6,"percentile":1}}},"demographics":{"users":{"mendeley":{"by_status":[],"by_discipline":[]}}},"posts":{"facebook":[{"title":"Treatment of Neuromyelitis Optica: Current Debate","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1336743229707071&id=454973074550762","license":"public","citation_ids":[19699005],"posted_on":"2017-04-25T09:53:02+00:00","summary":"Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that largely affects optic nerves and spinal cord. Recent studies have identified an elevation of serum anti-aquaporin 4 antibody as a hallmark ...","author":{"name":"Neurology and Cannabinoids","url":"https:\/\/www.facebook.com\/454973074550762","facebook_wall_name":"Neurology and Cannabinoids","image":"https:\/\/graph.facebook.com\/454973074550762\/picture","id_on_source":"454973074550762"}}]}}